GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Short Interest

Y-Biologics (XKRX:338840) Short Interest


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Y-Biologics's Short Interest

For the Biotechnology subindustry, Y-Biologics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-Biologics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Short Interest distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Short Interest falls into.


Y-Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Short Interest
Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Website
https://www.ybiologics.com
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics Headlines

No Headlines